About Sofregen
Sofregen is a company based in Medford (United States) founded in 2014 by Anh Hoang.. Sofregen has raised $17.8 million across 2 funding rounds from investors including Anzu Partners and Polaris Partners. The company has 8 employees as of December 31, 2021. Sofregen has completed 1 acquisition, including SERI Surgical Scaffold. Sofregen offers products and services including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform. Sofregen operates in a competitive market with competitors including Revance Therapeutics, Kerecis, Castle Creek Pharma, Organogenesis and Dermavant, among others.
- Headquarter Medford, United States
- Employees 8 as on 31 Dec, 2021
- Founders Anh Hoang
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sofregen Medical Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.8 M (USD)
in 2 rounds
-
Latest Funding Round
$8.1 M (USD), Series B
Sep 03, 2019
-
Investors
Anzu Partners
& 1 more
-
Employee Count
8
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sofregen
Sofregen offers a comprehensive portfolio of products and services, including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Injectable biomaterial for vocal fold medialization and regeneration procedures.
Biomaterial scaffold for soft tissue support in surgical applications.
Platform for developing silk-based products for tissue regeneration.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Sofregen
Sofregen has successfully raised a total of $17.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8.1 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $8.1M
-
First Round
First Round
(27 Sep 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Series B - Sofregen | Valuation | Anzu Partners |
|
| Sep, 2017 | Amount | Series A - Sofregen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sofregen
Sofregen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Anzu Partners and Polaris Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in industrial and life sciences technology companies.
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sofregen
Sofregen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SERI Surgical Scaffold. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone plastic surgery hospital services are provided in Medford.
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Sofregen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sofregen Comparisons
Competitors of Sofregen
Sofregen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Kerecis, Castle Creek Pharma, Organogenesis and Dermavant, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Fish-skin acellular dermal matrix technology is provided for wound treatments.
|
|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Regenerative therapies for wound care are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sofregen
Frequently Asked Questions about Sofregen
When was Sofregen founded?
Sofregen was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Sofregen located?
Sofregen is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Who is the current CEO of Sofregen?
Jenna Abelli is the current CEO of Sofregen.
Is Sofregen a funded company?
Sofregen is a funded company, having raised a total of $17.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $9.7M, raised on Sep 27, 2017.
How many employees does Sofregen have?
As of Dec 31, 2021, the latest employee count at Sofregen is 8.
What does Sofregen do?
Sofregen is developing the use of silk in a variety of forms to help physicians address soft tissue defects. The technology was developed at Tufts University and the University of Pittsburgh. As part of their growing portfolio of medical technologies, they have recently become the new supplier of SERI Surgical Scaffold, the only silk-based biological mesh. Unlike other products that are derived from human cadaver or animal tissue, SERI Surgical Scaffold is an ultra-pure, sterile, silk-derived bioprotein that is claimed to be delivering consistent and predictable characteristics and facilitating native tissue generation over time.
Who are the top competitors of Sofregen?
Sofregen's top competitors include Revance Therapeutics, Kerecis and Dermavant.
What products or services does Sofregen offer?
Sofregen offers Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform.
How many acquisitions has Sofregen made?
Sofregen has made 1 acquisition, including SERI Surgical Scaffold.
Who are Sofregen's investors?
Sofregen has 2 investors. Key investors include Anzu Partners, and Polaris Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.